NSCLC: Cardiotoxicity common after high-dose thoracic radiotherapy

Cardiac events were relatively common following high-dose thoracic radiotherapy among patients with stage III non-small cell lung cancer (NSCLC) treated between 1996 and 2009, according to a study published in the Journal of Clinical Oncology.
Cancer Therapy Advisor